and are not tumorigenic in animal studies [11] . In addition, human embryonic stem cells (hESCs) are highly promising for regenerative medicine because of their rapid proliferation to provide an unlimited supply of stem cells. hESCs can differentiate into all types of bone-related cells, such as mesenchymal cells, osteoblasts, endothelial cells and neurons [12] [13] [14] . Indeed, progress has been achieved by seeding hESCs on scaffolds for tissue regeneration [15] . Recently, human induced pluripotent stem cells (hiPSCs) were generated from adult somatic cells by reprogramming techniques, and were presented as a promising source of progenitor cells [16] . Patient-specific hiPSCs can potentially differentiate into cells of all three germ layers [17] . hiPSCs are believed to be similar to hESCs in many respects, including the expression of certain stem cell genes and proteins, doubling time, chromatin methylation patterns, embryoid body formation, viable chimera formation, potency and differentiability [18] . MSCs were derived to reduce the risk of tumorigenesis of pluripotent stem cells and embryonic stem cells [19] . The resulting hiPSC-derived MSCs (hiPSC-MSCs) and hESC-derived MSCs (hESC-MSCs) are promising for regenerative therapy.
Scaffolds are needed in bone engineering. Pre-formed scaffolds have drawbacks, including the difficulty of seeding cells deep into the scaffold and inability to inject them in minimally invasive surgery [20] . Therefore, injectable hydrogel scaffolds have been developed [2] . However, injectable hydrogel scaffolds with cell encapsulation are not strong enough for load-bearing purposes [21] . They do not possess the mechanical strength for use in load-bearing applications for bone regeneration [2] . To date, there are no injectable, bioactive and mechanically strong scaffolds available for stem cell encapsulation in clinical applications.
Previous studies encapsulated cells in alginate hydrogel microbeads, which were then mixed with a calcium phosphate cement (CPC) paste [22] [23] [24] . After injection, the CPC sets to form a moderately loadbearing scaffold, and the microbeads degrade and release the cells throughout the CPC scaffold [22] [23] [24] . However, upon degradation, the microbeads create spherical pores in the CPC with limited interconnection. Sufficient pore interconnection is required for cell migration, cell-cell interactions and tissue ingrowth. Fibers have an advantage over beads because when fibers dissolve they create long cylindrical channels throughout the CPC scaffold. Therefore, in the present study, stem cells were encapsulated in long alginatefibrin hydrogel fibers which were then mixed into CPC for the first time.
The objectives of this study were: (1) to develop a novel injectable CPC construct containing hydrogel fibers encapsulating stem cells for bone engineering, and (2) to investigate cell viability, proliferation and osteogenic differentiation by comparing hiPSC-MSCs, hESC-MSCs and hUCMSCs. The following proposals were tested: (1) CPC with stem cell-encapsulating fibers could be fully injectable, and the injection would not harm the cells in the paste; (2) the injectable cellencapsulating construct would have excellent mechanical properties; (3) hiPSC-MSCs, hESC-MSCs and hUCMSCs encapsulated in fibers in CPC would have excellent viability and proliferation, and would be able to differentiate into an osteogenic lineage; (4) all three types of cells in CPC would have high levels of osteogenic gene expression and synthesize bone minerals with a similarly high potential for bone engineering.
Materials and methods

Culture of hiPSCs and derivation of MSCs
The use of hiPSCs, hESCs and hUCMSCs was approved by University of Maryland Institutional Review Board. The hiPSC BC1 line was derived from adult bone marrow CD34 + cells which were reprogrammed by a single episomal vector pEB-C5, as previously described [25] . hiPSCs were maintained on mitotically inactivated murine embryonic fibroblast (MEF) feeder cells in hiPSC medium [25] . hiPSC medium consisted of 80% Dulbecco's modified Eagle's medium (DMEM)/F12 (Invitrogen, Carlsbad, CA, USA), 20% Knockout Serum Replacement (a serum-free formulation, Invitrogen), 1% MEM non-essential amino acids solution, 10 ng ml −1 basic fibroblast growth factor (β-FGF, Invitrogen), 1 mM l-glutamine (Sigma) and 0.1 mM β-mercaptoethanol (Sigma). hiPSCs were detached from a feeder layer and dissociated into clumps through treatment with 1 mg ml −1 collagenase type IV in DMEM/F12 at 37 °C for 6 min. The dissociated hiPSC clumps were collected by sedimentation, re-suspended in embryoid body (EB) differentiation medium (the same formulation as hiPSC culture medium but without β-FGF) and transferred to 25 cm 2 ultra-low attachment cell culture flasks (Corning, Corning, NY, USA) [25] .
After 10 d, the EBs were transferred onto 0.1% gelatin-coated culture dishes [25] . Cells growing out from EBs were cultured, and upon 70% confluence the outgrowth cells (P0) were selectively isolated by using cell scrapers and sub-cultured in MSC growth medium. This medium consisted of low-glucose DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA), 100 U ml −1 penicillin and 100 mg ml −1 streptomycin (PS, Gibco). The differentiated cells from these culture conditions were passaged until a homogeneous fibroblastic morphology appeared. They were termed hiPSC-derived MSCs (hiPSC-MSCs) [25] . Our previous study confirmed that the hiPSC-MSCs generated from this method expressed surface markers characteristic of MSCs (CD29, CD44, CD166, CD73), and were negative for typical hematopoietic (CD34), endothelial (CD31) and pluripotent markers (TRA-1-81 and OCT 3/4) [26] . The fourth passage hiPSC-MSCs were used in subsequent experiments.
Culture of hESCs and derivation of MSCs
The culture of hESCs (H9, Wicell, Madison, WI, USA) followed the Wicell protocol. hESCs were first induced to form EBs following a protocol similar to that described for hiPSCs [5, 27] . The out-growing cells were passaged until a homogeneous fibroblastic morphology appeared [5] . They were termed hESCderived MSCs (hESC-MSCs) [5] . Our previous study confirmed that these hESC-MSCs express surface markers characteristic of MSCs (CD29, CD44, CD73 and CD166) and are negative for hematopoietic markers (CD31, CD34, CD45) and pluripotent markers (TRA-1-81 and Oct3/4) [15] . The fourth passage hESCMSCs were used.
hUCMSC culture
hUCMSCs were obtained from ScienCell (Carlsbad, CA, USA), which were harvested from the Wharton's jelly in umbilical cords of healthy babies. hUCMSCs were cultured in DMEM with 10% FBS and 1% PS [28] . Immunophenotyping via flow cytometry showed that hUCMSCs expressed high levels of adhesion markers (CD29 and CD44) and MSC-specific antigen CD105 (also called SH2), as described previously [28] . The cells were positive for HLA-class I (HLA-ABC) and negative for HLA-class II (HLA-DR). They did not express endothelial (CD31) or hematopoietic lineage markers (CD34 and CD45). This phenotype is characteristic for MSCs [28, 29] . The fourth passage cells were used in subsequent experiments.
Cell encapsulation in alginate-fibrin fibers
Alginate was used for cell encapsulation because it is non-cytotoxic and can form ionic cross-linkages with multivalent cations under mild conditions without harming the cells [30] . However, alginate degrades slowly and uncontrollably. A previous study developed a method to control alginate gel degradation via partial periodate oxidation [31] . Our previous study used 7.5% oxidation and showed fast cell release from microbeads [23] . In the present study, alginate (64% guluronic acid, MW = 75 000-220 000 g mol −1 ; ProNova, Oslo, Norway) was oxidized at 7.5% oxidation [23] . Cell-encapsulating alginate fibers were synthesized using a wet spinning technique, which consisted of the extrusion of a solution through a needle into a coagulation bath [32] . A 2% sodium alginate solution was prepared by dissolving alginate in a 155 mM sodium chloride solution at 37 °C. This was followed by the addition of fibrinogen from bovine plasma (Sigma) at a concentration of 0.4% [33] . Cells were added to the alginate-fibrinogen solution at a density of 1 × 10 6 cells ml −1 . The cell-alginate suspension was loaded into a 5 ml syringe. The cell-encapsulating alginate-fibrin fibers were obtained by extruding the cell-alginate suspension through a 27-gauge needle (with 210 µm inner diameter) via a syringe pump (NE-300 Single Syringe Pump, New Era Pump Systems, Farmingdale, NY, USA) at a rate of 6 ml min −1 . The cell-alginate suspension was extruded into a 100 ml bath which consisted of 100 mmol l −1 calcium chloride (Sigma) and 1 NIH unit ml -1 of thrombin (Sigma). When the alginate-fibrinogen streamed into the bath, the presence of Ca 2+ ions initiated ionotropic gelation by counterbalancing the negative charges of alginate, while the reaction between fibrinogen and thrombin produced fibrin [23, 32] . The alginate-fibrin fibers were allowed to cross-link in the bath for 20 min [32] . Then the alginate-fibrin fibers were collected and washed with phosphate-buffered saline (PBS). This method resulted in the cell-encapsulating alginatefibrin fibers. These fibers were examined using a light microscope (TE2000-S, Nikon, Melville, NY, USA). The fiber formed in the cross-linking bath was a single continuous fiber. During handling, and for ease of mixing with CPC paste, the fibers were broken into lengths of 15 mm, as described in section 2.5. These cell-encapsulating alginate-fibrin fibers were referred to as 'CAF'.
Injectability testing of CPC pastes containing cell-encapsulating fibers
CPC powder consisted of tetracalcium phosphate (TTCP; Ca 4 (PO 4 ) 2 O) and dicalcium phosphate anhydrous (DCPA; CaHPO 4 ) [24] . TTCP was synthesized using DCPA and calcium carbonate (both from J T Baker, Philipsburg, NJ, USA) which were mixed and heated at 1500 °C for 6 h in a furnace (Model 51333, Lindberg, Watertown, WI, USA). The heated mixture was quenched to room temperature, ground in a ball mill (Retsch PM4, Brinkman, NY, USA) and sieved to obtain TTCP powder with a median particle size of 5 µm. The commercial DCPA powder was ground for 24 h in the ball mill in 95% ethanol and sieved to obtain a median particle size of approximately 1 µm. Then the TTCP and DCPA powders were mixed at 1:3 molar ratio in a micro-mill (Bel-Alert Products, Pequannock, NJ, USA) to form the CPC powder. Chitosan could render the CPC paste fast-setting and mechanically strong [34] . Therefore, chitosan lactate (Vanson, Redmond, WA, USA) was mixed with water at chitosan/(chitosan + water) mass fractions of 0%, 5%, 10% and 15%, respectively, to serve as four different CPC liquids. The CAF were cut into lengths of approximately 15 mm and mixed with CPC paste at a fiber volume fraction of 50%. The CAF were flexible and were randomly bent and oriented in the CPC paste. For mechanical reinforcement, an absorbable suture fiber (Vicryl, polyglactin 910, Ethicon, Somerville, NJ, USA) was cut to 3 mm lengths and mixed into the CPC paste at 10% by volume, which could provide the necessary early strength to the CPC scaffold for several weeks [35] . The quantities of 10% suture fibers and 50% alginate volume fraction in CPC were based on previous studies [24, 36] . Since the chitosan and suture fiber additions influenced the injectability of the paste, testing was done versus chitosan (0%, 5%, 10% and 15%) and suture fiber content (0%, 10%). Therefore, eight CPC pastes were tested for injectability (chitosan is denoted as CN and suture fiber as SU):
(1) CPC paste using water as the liquid, 0% chitosan (CPC control); (2) CPC paste using water as the liquid, 0% chitosan + 50% cell-encapsulating alginatefibrin fibers (CPC-CAF); (3) CPC + 5% chitosan liquid + 50% cellencapsulating alginate-fibrin fibers (CPC-5CN-CAF); (4) CPC + 5% chitosan liquid + 50% cellencapsulating alginate-fibrin fibers + 10% suture fibers (CPC-5CN-CAF-SU); (5) CPC + 10% chitosan liquid + 50% cellencapsulating alginate-fibrin fibers (CPC-10CN-CAF); (6) CPC + 10% chitosan liquid + 50% cellencapsulating alginate-fibrin fibers + 10% suture fibers (CPC-10CN-CAF-SU); (7) CPC + 15% chitosan liquid + 50% cellencapsulating alginate-fibrin fibers (CPC-15CN-CAF); (8) CPC + 15% chitosan liquid + 50% cellencapsulating alginate-fibrin fibers + 10% suture fibers (CPC-15CN-CAF-SU).
To test injectability, a 10 ml syringe (Free-Flo, Kerr, Romulus, MI, USA) with an opening tip of 2.7 mm (which is similar to the inner diameter of a 10-gauge needle) was used as in a previous study [24] . Ten-gauge needles are similar to spinal needles used in augmentation of osteoporotic vertebrae and the management of vertebral compression fractures. Each CPC powder and liquid (2:1 mass ratio) were mixed using an automatic mixer (Maxi Mix, Thermolyne, Dubuque, IA, USA) for 15 s. The paste was placed into the syringe, which was pressed via a comp utercontrolled universal testing machine (MTS, Eden Prairie, MN, USA) at a crosshead speed of 15 mm min −1 [18] . The percentage of extruded paste was determined as the mass of the extruded paste divided by the original mass of paste in the syringe. The injection force was recorded by the computer and the maximum force during injection was used as the injection force for the specific paste [24] . Six samples were tested for each group.
Mechanical testing of CPC scaffold containing cell-encapsulating fibers
C P C p a s t e w a s p l a c e d i n t o a m o l d o f 3 mm × 4 mm × 25 mm and incubated in a humidor for 4 h at 37 °C. The set CPC specimens were demolded and immersed in culture medium at 37 °C for 1 d [35] . A three-point flexural test with a span of 20 mm was used to fracture the specimens on a Universal Testing Machine at a displacement rate of 1 mm min
. Flexural strength was calculated by S = 3F max L/(2bh 2 ), where F max is the maximum load on the load-displacement (F-d) curve, L is the span, b is the specimen width and h is the thickness. The elastic modulus was calculated
, where load F divided by displacement d is the slope in the linear elastic region. Six specimens were tested for each group.
Viability of encapsulated hESC-MSCs, hiPSC-MSCs and hUCMSCs
hiPSC-MSCs, hESC-MSCs and hUCMSCs were each encapsulated in alginate-fibrin fibers. To evaluate if mixing and injecting the CPC paste would harm the encapsulated cells, cell viability was examined without injection and after injection in CPC-15CN-CAF-SU paste. The paste was injected from a 10 ml syringe as described above. The CPC paste was removed and the CAF were collected immediately after injection. The CAF were then stained with a live/dead kit. The percentage of live cells and the live cell density were measured.
To evaluate the cell release behavior from CAF, 200 µl of CAF with each cell type was added to a well with 2 ml of MSC growth medium. At predetermined time points (1, 4, 7 and 14 d), the CAF morphology and cells were examined with an optical microscope (TE2000-S, Nikon) following a previous study [23] . To further examine the release of cells from CAF inside the CPC, the CAF were placed inside the CPC paste, using a method described previously [37] . First, 0.1 g of a CPC paste was placed to cover the bottom of a well (15 mm diameter) of a 24-well plate and the surface of the CPC paste was flattened. Then, 200 µl of CAF was placed on the CPC, and another 0.1 g of CPC paste was used to completely cover the CAF. The purpose of this setup was to provide a flat-bottomed CPC surface, so that the cells released from the CAF could attach to CPC to enable live/dead staining and microscopic examination. Ideally, the CAF should be randomly mixed with CPC paste; however, subsequent breakage of the CPC scaffold for analysis would create rough and tortuous surfaces unsuitable for microscopic examination. In the present study, the CAF were completely trapped inside the CPC, enabling a test of cell survival inside CPC (cells which would rely on the interconnected pores in the CPC for fluids and nutrition). The construct was incubated at 37 °C for 30 min, then 2 ml of the osteogenic medium was added to each well to submerge the construct. At 1, 4, 7 or 14 d, the constructs were opened and the bottom CPC layer was used for analysis. The bottom CPC layer was immersed in a live/dead staining solution (Invitrogen, Carlsbad, CA, USA). For each cell type and each time period, six wells were used for live/dead staining, and six wells were used for the cell proliferation assay. The cells were examined with an epifluorescence microscope (Eclipse TE-2000S, Nikon). Three images were taken at random locations for each sample, with 6 samples yielding 18 images for each cell type at each time point A cell counting kit (CCK-8, Dojindo, Tokyo, Japan) was used to evaluate cell proliferation from 1 to 14 d in CPC-CAF constructs. CCK-8 is based on the WST-8 reaction that produces an orange formazan dye in an amount that is directly related to the number of viable cells [38] . After breaking the CPC cover, the bottom CPC layer was immersed in 2 ml of culture medium containing 10% CCK-8, and incubated in the dark for 1.5 h. Then 100 µl of the medium was transferred to a new 96-well plate. The cell proliferation rate was determined via the absorbance at an optical density of 450 nm (OD 450 nm ) using a microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA), following a previous study [38] . WST-8 was reduced by dehydrogenase activities in the cells to give a yellow-colored formazan dye, which was soluble in culture medium. The amount of formazan dye from dehydrogenase in the cells was directly proportional to the number of living cells [38] . In addition, to investigate cell-CPC scaffold interactions, CPC-15CN-CAF-SU samples with cells at 14 d were examined by scanning electron microscopy (SEM; FEI Quanta 200, Hillsboro, OR, USA). The samples were dehydrated, sputter-coated with gold and then viewed by SEM.
Differentiation of encapsulated hESC-MSCs, hiPSC-MSCs and hUCMSCs
The aforementioned CPC-15CN-CAF-SU constructs containing the three types of cells were cultured in osteogenic medium. At 1, 4, 7 and 14 d, the total RNA of the collected cells was extracted with TRIzol reagent and PureLink RNA Mini Kit (Life Technologies). Briefly, total RNA was extracted from homogenized constructs using 500 µl of TRIzol for each well. A PureLink RNA Mini Kit was used for isolation and purification of total RNA, following the manufacturer's instructions. The concentration and purity of total RNA was assessed using a NanoDrop 2000 ™ (Thermo Scientific, Waltham, MA, USA). The absorbance ratio of A260/A280 was used as an indicator of protein contamination. A total of 1000 ng of RNA was used to perform the reverse transcription into cDNA using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) in a thermal cycler (GenAmp PCR 2720, Applied Biosystems). TaqMan gene expression kits (Applied Biosystems) were used to quantify the targeted genes on human alkaline phosphatase (ALP; Hs00758162_ ml), Runt-related transcription factor (RUNX2; Hs00231692_ml), collagen type-I, alpha 1 (COL1A1; Hs00164004_m1), osteocalcin (OC; Hs00609452_ g1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Hs99999905_m1; reference gene). Relative expression was evaluated using the 2 C t −∆∆ method and normalized by C t of the housekeeping gene GAPDH. C t of hiPSC-MSCs, hESC-MSCs, and hUCMSCs in control medium at 1 d served as a calibrator. The 14 d culture followed previous studies [10, 24, 37].
Mineral synthesis via encapsulated hiPSC-MSCs, hESC-MSCs and hUCMSCs
The aforementioned CPC-15CN-CAF-SU encapsulating the three types of cells was cultured in osteogenic medium. After 1, 7 and 14 d, two methods were used to investigate mineral synthesis by the encapsulated cells in vitro. First, xylenol orange was used; this is a fluorescent probe that can chelate to calcium and stains the mineral a red color. It is not harmful to cells and the staining can be performed on live cells [39] . Because CPC could chelate with xylenol orange, the method was modified to avoid a strong background in images. Two hundred microliters of CAF was placed on the polystyrene bottom of each well of 24-well plate, then 0.1 g of CPC paste was used to completely cover the CAF. At 1, 7 or 14 d, CPC was removed and the CAF were incubated overnight in 2 ml of osteogenic medium containing xylenol orange at a concentration of 100 µM. In this way, only the CAF were stained, without interference from CPC which was removed and not stained. Mineral nodules were observed by epifluorescence microscopy (Eclipse TE-2000S, Nikon). The percentage area of mineralization was calculated as A Mineral /A Total , where A Mineral is the area of mineralization (red fluorescence) in the image and A Total is the total area of the image [24] .
Second, separate CPC-15CN-CAF-SU constructs were cultured and Alizarin red S (ARS) staining was performed. The CPC bottom layer with the attachment of released cells was washed with PBS, fixed in 10% formaldehyde and stained with 2% ARS (Millipore, Billerica, MA, USA) for 5 min (this stains calciumrich deposits made by the cells as a dark red color) [36, 37, 40] . An osteogenesis assay kit (Millipore) was used to extract the stained minerals and measure the Alizarin red concentration, following the manufacturer's instructions [36, 37, 40] . The ARS standard curve was made with a known concentration of the dye. The CPC scaffold with the same composition as the cell construct, but without cells, was cultured in the same medium for the same time periods and used as control. At each time period of culture, the ARS concentration in the CPC controls was subtracted from the ARS concentration of the CPC-15CN-CAF-SU constructs containing cells, to yield the net mineral concentration synthesized by the cells, following previous studies [36, 37, 40] .
Statistical analyses
Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS 16.0, Chicago, IL, USA). Significance was assessed with one-and twoway analyses of variance (ANOVA), Tukey's multiple comparison test and Student-Newman-Keuls test at p = 0.05. All data were expressed as the mean value ± one standard deviation (SD).
Results
The diameter of CAF fiber (mean ± SD; n = 50) was measured to be 220 ± 28 µm. The injectability results for CPC containing these fibers are plotted in figure 1: (A) percentage of paste extruded and (B) injection force (mean ± SD; n = 6). In (A), nearly all the CPC paste in the syringe was smoothly extruded, and there was no significant difference between any of the groups (p > 0.1). In (B), while all the injection forces were relatively small, the forces for the other groups were significantly higher compared with the CPC control (p < 0.05). Adding CN and SU increased the injection force (p < 0.05). The maximum injection force for group 7 was 43.1 ± 7.9 N, which was still relatively small and could be readily performed manually by surgeons. These results demonstrate that all these CPC pastes were injectable.
The mechanical properties of CPC are plotted in figure 2 : part (A) shows typical load-displacement curves, (B) flexural strength, and (C) elastic modulus (mean ± SD; n = 6). In (A), load-displacement curves are shown for CPC-15CN-CAF and CPC-15CN-CAF-SU as examples. Other materials had similar fracture behavior except with smaller peak loads at failure. Adding CN and SU enhanced the strength (p < 0.05). CPC-15CN-CAF-SU had the highest strength, 8.5 ± 0.8 MPa, which was more than three times that of the CPC control (p < 0.05). The three bars on the right-hand side indicate the strength of cancellous bone and other injectable carriers for cell delivery reported in the literature. The elastic moduli of the modified CPCs were lower than the CPC control because CPC was brittle and stiff, while CN and SU were flexible. These results demonstrate that CPC-15CN-CAF-SU had mechanical properties exceeding those of cancellous bone and previous injectable cell carriers. Figure 3 shows hiPSC-MSCs encapsulated in hydrogel fibers without CPC and without injection, and hiPSC-MSCs mixed in CPC paste and injected: parts (A) and (B) are cell live/dead staining images, part (C) shows the percentage of live cells, and part (D) the live cell density (mean ± SD; n = 6). The images for the other two types of cells were similar. Live/dead staining images showed little difference, indicating that the mixing and injection of CPC paste did not significantly harm the cells. In addition, there was no noticeable difference between the three types of cells. This was verified in the quantitative measurements in (C) and (D) (p > 0.1). Mineral synthesis by cells in CPC-CAF is shown in figure 6 by two methods: (A)-(D) xylenol orange staining, and (E)-(H) ARS staining. Figures 6(A)-(C) show representative images of xylenol orange staining for hiPSC-MSCs; images for the other two types of cells were similar. In (D), the mineral synthesis (mean ± SD; n = 6) increased about six-fold from 1 to 14 d (p < 0.05). Figures 6(E)-(G) show representative images of ARS staining of hESC-MSCs; images of the other two cell types were similar. From 1 to 14 d, the red staining of the synthesized bone mineral matrix covering the bottom surface of the CPC became a denser and darker red. In figure 6(H) , the cell-synthesized mineral concentration was increased by about 13-fold from 1 to 14 d (p < 0.05). For both (D) and (H), at each time period, there was no significant difference between hiPSC-MSCs, hESC-MSCs and hUCMSCs (p > 0.1).
Discussion
The present study derived MSCs from hiPSCs and hESCs, and compared hiPSC-MSCs, hESC-MSCs and hUCMSCs encapsulated in hydrogel fibers in injectable CPC for the first time. The oxidized alginate-fibrin fibers were shown to be suitable for cell encapsulation, and for protecting the cells from the processes of CPC paste mixing and injection. Cells in the alginate-fibrin fibers could be quickly released to start their attachment and proliferation in the CPC scaffold. The injectable CPC, reinforced by chitosan and degradable suture fibers, had good affinity for cell attachment and showed no negative effect on cell viability after injection, compared with uninjected cells. All three types of stem cells underwent osteogenic differentiation in CPC. Therefore, this study showed that hiPSC-MSCs, hESC-MSCs and hUCMSCs are all promising cell sources for bone regeneration, and the novel injectable CPC-CAF can be used to deliver stem cells for bone tissue engineering. Hydroxyapatite (HA) and other CaP bioceramics are of importance for bone repair due to their excellent biocompatibility and bioactivity [41] [42] [43] [44] . When implanted in an osseous site, bioactive materials provide an ideal environment for cellular reaction and colonization by osteoblasts. This leads to a tissue response termed osteoconduction, in which bone grows on and bonds to the implant, promoting a functional interface [45] . Indeed, hMSCs showed excellent viability and differentiation on HA scaffolds [46] . However, sintered HA implants are generally not bioresorbable. In addition, pre-formed bioceramics require machining and may leave gaps when they are fitted into a bone cavity. This could lead to increases in bone loss, trauma and surgical time [20] . In contrast, CPC can be injected with precise adaptation to complex defects [47] , can be easily shaped for esthetics in dental and maxillofacial repairs and is osteoconductive and bioresorbable. The present study showed that with increasing chitosan concentration as well as suture fiber incorporation, the injection force needed for CPC was increased. However, the maximum injection force of 43 N was still small. An injection force of less than 100 N required to extrude a cement paste containing a polymer gel was regarded as being 'injectable' [47] . The CPC-15CN-CAF-SU paste in the present study was fully extruded at a much smaller force and hence can be regarded as being injectable. Besides injectability, the mechanical properties of the set scaffold after injection are also important. Traditional CPC is relatively brittle and weak, and hence its use is limited to the reconstruction of non-stressbearing bone [48, 49] . In the present study, the flexural strength was increased with increasing concentration of chitosan and with the addition of absorbable suture fibers. A previous study reported a tensile strength of 3.5 MPa for cancellous bone [50] . Other studies reported that the strength was 0.7 MPa for injectable polymeric carriers for cell delivery [51] and 0.1 MPa for hydrogels [21] . The elastic modulus was 0.30 GPa for cancellous bone, 0.008 GPa for injectable polymeric carriers and 0.0001 GPa for hydrogels. These carriers are good for tissue engineering in non-loading-bearing locations. In contrast, the injectable CPC-15CN-CAF-SU of the present study was much stronger mechanically, with potential for a wide range of moderate loadbearing bone repairs. Cell delivery methods are important for tissue engineering [52, 53] . Traditionally, a cell suspension is placed onto the surface of a scaffold, with limitations including low seeding efficacy and minimal cell penetration into the scaffold [54] . For CPC, it is not feasible to directly mix the cells into the paste, because the mixing forces and the ionic exchanges during CPC setting would harm the cells. Our previous studies developed alginate microbeads to encapsulate cells which were then mixed into CPC paste [15, 23, 37] . During the CPC setting and injection process, the microbeads protected the cells. After the CPC had set, the microbeads then dissolved and released the cells inside the CPC scaffold. However, microbead degradation created spherical pores in CPC with limited pore interconnectivity; for example, a microbead with a diameter of 200 µm would create a 200 µm pore in the CPC. Encapsulating cells in hydrogel fibers could have advantages over microbead encapsulation. These cell-encapsulating fibers can degrade and release the cells in CPC, creating long macropore channels. For example, a fiber of diameter 200 µm and length 15 mm would create a long macropore of diameter 200 µm and length 15 mm. This is beneficial in allowing oxygen and nutrients to reach the internal cells, and in providing more space for cells to communicate with each other in the CPC. Furthermore, the CPC-CAF method overcame the drawback of using hydrogel alone without CPC. The drawbacks of hydrogel include the inability to withstand pressure in load-bearing sites and to maintain shape and contour integrity [55] . Due to the fast-degradable CAF, after CPC setting, cell release started at 4 d, followed by cell spreading and proliferation. The fast release of cells was due to oxidized alginate and fibrin formation via the reaction between fibrinogen and thrombin [23] . In addition, other applications of long hydrogel fibers loaded with cells could include the formation and ingrowth of blood vessels in CPC scaffolds in vivo, which require further study.
Three types of cells were investigated in the present study. Previous studies showed that hUCMSCs had an excellent osteogenic effect when delivered via CPC scaffolds [24] . hESCs are also promising for bone regeneration due to their high proliferation. In addition, hiPSCs from adult somatic cells have several features similar to hESCs. In the present study, MSCs were derived from hiPSCs and hESCs, because MSCs can self-renew and differentiate into various tissues, including bone [12] . A previous report showed that hiPSC-MSCs and hUCMSCs had similar proliferation when seeded on a CPC scaffold [29] . Another study reported that hESCs and hiPSCs had similar characteristics and therapeutic effects for nerve regeneration [56] . These results are consistent with the present study showing that hiPSCMSCs, hESC-MSCs and hUCMSCs had similarly good proliferation in CPC constructs.
The encapsulated hiPSC-MSCs, hESC-MSCs and hUCMSCs in CPC showed elevated levels of ALP, RUNX2, COL1A1 and OC gene expressions. The cellsynthesized bone matrix minerals increased with time. This indicates that the encapsulated cells in CPC were differentiated into the osteogenic lineage. RT-PCT showed that ALP and OC peaked at 14 d. RUNX2 and COL1A1 generally peaked at 7 d, although the 7 and 14 d peaks were not significantly different. ALP is a well-defined marker for osteogenic differentiation that is expressed in the early stage of MSC osteogenesis, and its up-regulation is a prerequisite for mineralization and subsequent maturation of bone [57] . RUNX2 is essential for osteoblastic differentiation and acts as a regulatory factor involved in osteogenic-related gene expression [58] . The extracelluar matrix-related collagen I is another marker for bone formation. Collagen I mediates cell adhesion and osteoblast phenotype formation, and provides a template for mineralization. In addition, OC is a bone-specific protein synthesized by osteoblasts that represents a good marker for osteogenic maturation. Our previous study showed that MSCs could have ALP peaks at 7 d if they were directly seeded on a CPC scaffold [29] . However, in the present study, the cells were encapsulated in hydrogel fibers, which delayed the release of the cells into the CPC scaffold, thereby delaying the ALP expression peak to 14 d. Similarly, a previous study with hMSCs encapsulated in alginate microbeads also exhibited an ALP peak at 14 d [15] . A previous study reported OC peaking at 8 d [57] . In the present study, although the OC expression at 7 d was quite high, the peaks at 14 d were slightly higher than those at 7 d, indicating that OC expression by these cells may continue to increase after 8 d.
Previous studies reported that RUNX2 was bound with OC promoter and was expressed in osteochondral progenitors and in early stages of osteogenic differentiation [59] . The present study showed that RUNX2 was up-regulated from 4 d and peaked at 7 d for all three types of stem cells, and stayed high at 14 d. Previous studies showed that hypoxia inhibited osteogenesis in hMSCs through direct down-regulation of RUNX2 [60] . The up-regulation of RUNX2 indicates that the encapsulated cells in CPC-CAF were probably not subject to hypoxia. This is likely because the macroporous CPC allowed infiltration of oxygen and nutrients into the scaffold. Therefore, the high expressions of RUNX2 and other osteogenic genes verified that hiPSC-MSCs, hESC-MSCs and hUCMSCs had excellent osteogenic differentiation when encapsulated in the CPC-15CN-CAF-SU construct.
The osteogenic differentiation of cells in CPC-15CN-CAF-SU was further verified via mineralization. There was a substantial increase in mineralization over time for hiPSC-MSCs, hESC-MSCs and hUCMSCs. However, at 14 d, xylenol orange staining was six-fold higher than at 1 d, while ARS was 13-fold higher than at 1 d. This discrepancy was likely because xylenol orange shows 2D surface staining, while ARS reflects the 3D volume of minerals produced by the cells. With increasing time, the result from ARS was dependent not only on the increasing staining area, but also the greater thickness of the bone matrix synthesized by the cells. In the present study, both methods showed that: (1) there was a monotonic and substantial increase in cell mineralization with time for cells inside CPC-15CN-CAF-SU; (2) all three cell types, hiPSCMSCs, hESC-MSCs and hUCMSCs, synthesized bone minerals in CPC-15CN-CAF-SU; (3) the three types of cells had no significant difference in mineral synthesis. Therefore, hiPSC-MSCs, hESC-MSCs and hUCMSCs are all promising cell sources for bone tissue engineering, and the injectable and moderately load-bearing CPC-15CN-CAF-SU is promising for delivering stem cells for bone regeneration. Further in vivo experiments should be performed using an animal model to demonstrate the possibility of future clinical applications and to determine the effects of key variables in the injectable CPC-CAF-stem cell construct on bone regeneration efficacy.
Conclusion
This study developed an injectable CPC-hydrogel fiber-stem cell construct for the first time and compared hiPSC-MSCs, hESC-MSCs and hUCMSCs for bone tissue engineering. The mechanical properties of the injectable construct matched or exceeded those of cancellous bone, and were much higher than previous injectable cell-encapsulating polymers and hydrogels. The injection did not harm the viability of the encapsulated cells. hiPSC-MSCs, hESC-MSCs and hUCMSCs in CPC-15CN-CAF-SU all had excellent proliferation and differentiated into the osteogenic lineage, with highly elevated ALP, RUNX2, COL1A1 and OC expressions. The mineralization of hiPSCMSCs, hESC-MSCs and hUCMSCs in the injectable scaffold substantially increased over time. These results indicate that hiPSC-MSCs, hESC-MSCs and hUCMSCs are all promising cell sources for bone engineering. The novel injectable CPC scaffold with cell-encapsulating hydrogel fibers is promising for stem cell delivery to enhance bone regeneration in dental, craniofacial and orthopedic applications.
